Schizophrenia News and Research

Latest Schizophrenia News and Research

Biologists decipher molecular code regulating availability of brain channel linked to neuronal excitability

A key question in protein biochemistry is how proteins recognize "correct" interaction partners in a sea of cellular factors. Nowhere is that more critical to know than in the brain, where interactions governing channel protein activity can alter an organism's behavior.

23 Mar 2011

‘Sleeping sickness’ pandemic offers insight into Parkinson’s

A bizarre disease that caused sufferers to fall into a deep ‘sleep’ while still being aware of their surroundings can offer us insight into the nature of Parkinson’s disease.

21 Mar 2011

Physical ill-health reduces life expectancy of people with severe mental illness

Physical ill-health is rife among the severely mentally ill in Britain, according to new research published today by the University of East Anglia (UEA).

21 Mar 2011

Scientists to develop new MR imaging techniques for brain study

A Norwegian research centre is developing new magnetic resonance imaging techniques to study the brain. This could have impact for victims of brain damage as well as Alzheimer patients.

19 Mar 2011

Cortex reports net loss of $0.01 per share for quarter ended December 31, 2010

Cortex Pharmaceuticals, Inc. reported a net loss applicable to common stock of $984,000, or $0.01 per share for the quarter ended December 31, 2010 compared with a net loss of $1,599,000, or $0.02 per share for the corresponding prior year period.

18 Mar 2011

Researchers discover a type of 'cellular bilingualism' in brain

A team of researchers from the University of Montreal and McGill University have discovered a type of "cellular bilingualism" - a phenomenon that allows a single neuron to use two different methods of communication to exchange information.

18 Mar 2011

Cortex enters agreement with Biovail to regain AMPAKINE assets and rights

Cortex Pharmaceuticals, Inc. announced that it has entered into an agreement with Biovail Laboratories International SRL, a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc., to regain the AMPAKINE® assets and rights related to respiratory depression.

16 Mar 2011

New findings help explain why toxoplasmosis causes serious disease

Providing clues into why the severity of a common parasitic infection can vary greatly from person to person, a new Johns Hopkins study shows that each one of three strains of the cat-borne parasite Toxoplasma gondii sets off a unique reaction in the nerve cells it invades.

15 Mar 2011

Transcept initiates enrollment in TO-2061 Phase 2 study for treatment resistant obsessive compulsive disorder

Transcept Pharmaceuticals, Inc. today announced the first patient has been enrolled in a Phase 2 clinical study to evaluate TO-2061 as an adjunctive treatment for obsessive compulsive disorder (OCD) in patients who have responded inadequately to currently approved treatments. OCD affects 1 to 2 percent of the United States adult population and can significantly impair the lives of patients and their families.

14 Mar 2011

Scientists discover cerebrospinal fluid proteins are essential for brain building

Proteins in fluids bathing the brain are essential for building the brain, discover scientists in a report published March 10 in the journal Neuron. The finding promises to advance research related to neurological disease, cancer and stem cells.

14 Mar 2011

New technique may find 'hidden' receptors in nerve cells

Scientists at The Scripps Research Institute and University of Pennsylvania have found a way to uncover potential drug targets that have so far remained hidden from researchers' view.

11 Mar 2011

Future Medicine launches Neuropsychiatry

Future Medicine Ltd has today announced the launch of Neuropsychiatry – a new bimonthly title addressing all the latest trends in the field, from R&D through to clinical application and management, presenting research, findings, analysis and commentaries from experts around the world. Neuropsychiatry is published by Future Medicine Ltd (UK, London) renowned for its collection of journals providing healthcare practitioners and research professionals with a unique source of objective, cutting-edge information on exciting trends emerging in light of advances in medicine, healthcare and clinical practice.

10 Mar 2011

New study sheds 'light' on intricate brain cell connections responsible for anxiety

A new study sheds light--both literally and figuratively--on the intricate brain cell connections responsible for anxiety.

10 Mar 2011

EDT receives European approval for XEPLION injection to treat schizophrenia

Elan Drug Technologies, the drug delivery unit of Elan Corporation, plc, today announced that the first injectable product using EDT's NanoCrystal technology has been approved by the European Commission.

9 Mar 2011

NeuroDerm commences ND0611 Phase I/II trial to treat Parkinson's disease

NeuroDerm, Ltd. announced today the enrollment of the first group of patients in its Phase I/II clinical trial of ND0611, a new patch for the treatment of Parkinson's disease.

9 Mar 2011

New Australian drug approvals subject to budget cuts

According to Health Minister Nicola Roxon’s statement to pharmaceutical company bosses, new medicines will no longer be subsidised unless budget savings can be found.

9 Mar 2011

FDA accepts Lundbeck's clobazam NDA for review

Lundbeck Inc. today announced the U.S. Food and Drug Administration has accepted for review a New Drug Application for the investigational compound clobazam as adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome in patients two years and older.

5 Mar 2011

Scientific symposium to examine new approaches to schizophrenia drug development

Despite significant investment in research and development by pharmaceutical companies, the last decade has seen a marked decline in the number of drugs developed and approved for schizophrenia. A multi-day symposium at the New York Academy of Sciences on Wednesday, March 9 - Friday, March 11 will convene world-leading experts in clinical, translational, and basic neuroscience to address this problem by examining novel, state-of-the-art approaches to schizophrenia drug development.

5 Mar 2011